Pfizer and its German partner BioNTech SE said on Friday they have requested the US Food and Drug Administration to expand the emergency use of their COVID-19 vaccine in adolescents aged 12 to 15, Reuters reported.
In March, the drugmakers said the vaccine was found to be safe, effective and produced robust antibody responses in 12- to 15-year-olds in a clinical trial.
(Arutz Sheva’s North American desk is keeping you updated until the start of Shabbat in New York. The time posted automatically on all Arutz Sheva articles, however, is Israeli time.)
Read more